EDGAR Online

TRANZYME INC

Reported by

CASTAIGNE JEAN-PAUL

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 04/01/11 for the Period Ending 04/01/11

Address	4819 EMPEROR BOULEVARD, SUITE 400 DURHAM, NC 27703
Telephone	919 313-4760
CIK	0001274644
Symbol	TZYM
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2011, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Date of Event Requiring Statement (MM/DD/YYYY)	3. Issuer Name **and** Ticker or Trading Symbol
Castaigne Jean-Paul	**4/1/2011**	**TRANZYME INC [TZYM]**
(Last) (First) (Middle) **C/O TRANZYME, INC., 4819 EMPEROR BOULEVARD, SUITE 400**	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ **X** __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)	
(Street) **DURHAM, NC 27703** (City) (State) (Zip)	5. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ **X** _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	**8/9/2015**	**Common Exchangeable Shares of Tranzyme Pharma Inc.**	**389**	**$5.95**	**D**	
Stock Option (right to buy)	(2)	**8/9/2015**	**Common Exchangeable Shares of Tranzyme Pharma Inc.**	**714**	**$5.95**	**D**	
			Common				

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(2)	**8/10/2016**	**Exchangeable Shares of Tranzyme Pharma Inc.**	**714**	**$5.95**	**D**	
Stock Option (right to buy)	(3)	**2/1/2017**	**Common Exchangeable Shares of Tranzyme Pharma Inc.**	**714**	**$5.95**	**D**	
Stock Option (right to buy)	(3)	**4/10/2017**	**Common Exchangeable Shares of Tranzyme Pharma Inc.**	**714**	**$5.95**	**D**	
Stock Option (right to buy)	(4)	**2/19/2018**	**Common Exchangeable Shares of Tranzyme Pharma Inc.**	**2142**	**$5.95**	**D**	

Explanation of Responses:

(1) The entire option is fully vested and exercisable. When issued, the option was exercisable for Common Exchangeable Shares of Tranzyme Pharma Inc, which shares will be exchanged for shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011. After the closing of the Issuer's initial public offering, the option will be exercisable for shares of the Issuer's Common Stock.

(2) The entire option is fully vested and exercisable. When issued, the option was exercisable for Common Exchangeable Shares of Tranzyme Pharma Inc, which shares will be exchanged for shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011. After the closing of the Issuer's initial public offering, the option will be exercisable for shares of the Issuer's Common Stock.

(3) 25% of the shares vested and became exercisable on April 4, 2007, with the remainder vesting and becoming exercisable in equal quarterly installments for the following three quarters, so that the entire option is presently fully vested and exercisable. When issued, the option was exercisable for Common Exchangeable Shares of Tranzyme Pharma Inc, which shares will be exchanged for shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011. After the closing of the Issuer's initial public offering, the option will be exercisable for shares of the Issuer's Common Stock.

(4) 25% of the shares vested and became exercisable on May 1, 2008, with the remainder vesting and becoming exercisable in equal quarterly installments for the following three quarters, so that the entire option is presently fully vested and exercisable. When issued, the option was exercisable for Common Exchangeable Shares of Tranzyme Pharma Inc, which shares will be exchanged for shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011. After the closing of the Issuer's initial public offering, the option will be exercisable for shares of the Issuer's Common Stock.

Remarks:

Exhibit 24.1 Power of attorney

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Castaigne Jean-Paul				

C/O TRANZYME, INC. 4819 EMPEROR BOULEVARD, SUITE 400 DURHAM, NC 27703	**X**			

Signatures

/s/ Richard I. Eisenstadt, attorney-in-fact **4/1/2011**

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

***** If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Exhibit 24.1

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Vipin K. Garg and Richard I. Eisenstadt, and each of them individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

(1) Complete and execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or ten percent (10%) shareholder of Tranzyme, Inc., a Delaware corporation (the "Company") any Form ID and any and all instruments, certificates and documents required to be executed on behalf of the undersigned as an individual or on behalf of the undersigned's company or partnership, as the case may be, pursuant to Section 13 and Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or the rules and regulations thereunder;

(2) Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID or instruments, certificates or documents required to be filed pursuant to Sections 13 and 16 of the Exchange Act or the rules or regulations thereunder and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by either such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that either such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of March 15, 2011.

/s/ Jean-Paul Castaigne
Jean-Paul Castaigne, M.D.